PMID: 11903420Mar 21, 2002Paper

Losartan modifies glomerular hyperfiltration and insulin sensitivity in type 1 diabetes

Diabetes, Obesity & Metabolism
S NielsenC E Mogensen

Abstract

The effect of the angiotensin II receptor antagonist losartan on renal haemodynamics and insulin-mediated glucose disposal was examined in normotensive, normoalbuminuric type 1 diabetic patients using a double-blind, placebo-controlled, cross-over design. Diurnal blood pressure, glomerular filtration rate (GFR, determined using [125I]-iothalamate), renal plasma flow (RPF, determined using [131I]-hippuran) and urinary albumin excretion rate (UAE) were measured, and a hyperinsulinaemic, euglycaemic clamp with indirect calorimetry was performed in nine patients (age 30 +/- 7 years (mean +/- s.d.), HbA1c 8.1 +/- 1.1%) following 6 weeks' administration of either losartan 50 mg/day or placebo. Diurnal blood pressure was significantly reduced after losartan compared with placebo (122/70 +/- 11/8 vs. 130/76 +/- 12/6 mmHg, p < 0.05). A significant decline in GFR (133 +/- 23 vs. 140 +/- 22 ml/min, p < 0.05) and filtration fraction (FF; GFR/RPF) (24.6 +/- 3.5 vs. 26.2 +/- 3.6%, p < 0.05) was observed in the losartan vs. placebo groups. RPF and UAE did not change. Isotopically determined glucose disposal rates were similar after losartan and placebo in the basal (2.61 +/- 0.53 vs. 2.98 +/- 0.93 mg/kg/min) and insulin-stimulated states (6.8...Continue Reading

References

Jan 1, 1992·Journal of Cardiovascular Pharmacology·R A DeFronzo
Sep 1, 1992·The Journal of Clinical Investigation·R A LafayetteT W Meyer
Sep 1, 1988·Diabetic Medicine : a Journal of the British Diabetic Association·M M PedersenJ S Christiansen
Mar 1, 1988·Metabolism: Clinical and Experimental·E Ferrannini
Jul 24, 1986·The New England Journal of Medicine·H Yki-Järvinen, V A Koivisto
May 1, 1986·Scandinavian Journal of Clinical and Laboratory Investigation·C E Mogensen
Sep 1, 1971·Scandinavian Journal of Clinical and Laboratory Investigation·C E Mogensen
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Jun 1, 1996·Kidney International·B M BrennerH S Mackenzie
Jun 1, 1996·Kidney International·M BurnierH R Brunner
Sep 1, 1996·Hypertension·M LaaksoP Lempiäinen-Kuosa
Aug 1, 1996·Journal of Cardiovascular Pharmacology·J P FauvelM Laville
Jan 1, 1997·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·D C Wheeler

❮ Previous
Next ❯

Citations

Mar 19, 2003·Current Hypertension Reports·Raymond R Townsend
Jun 26, 2003·Journal of Internal Medicine·C E Mogensen
May 17, 2006·Diabetes/metabolism Research and Reviews·Maria Svensson, Jan W Eriksson
Feb 20, 2015·American Journal of Physiology. Renal Physiology·Tsjitske J ToeringA Titia Lely

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.